search icon
search icon
Flag Arrow Down
Română
Română
Magyar
Magyar
English
English
Français
Français
Deutsch
Deutsch
Italiano
Italiano
Español
Español
Русский
Русский
日本語
日本語
中国人
中国人

Change Language

arrow down
  • Română
    Română
  • Magyar
    Magyar
  • English
    English
  • Français
    Français
  • Deutsch
    Deutsch
  • Italiano
    Italiano
  • Español
    Español
  • Русский
    Русский
  • 日本語
    日本語
  • 中国人
    中国人
Sections
  • News
  • Exclusive
  • INSCOP Surveys
  • Podcast
  • EU
  • Diaspora
  • Republic of Moldova
  • Politics
  • Economy
  • Current Affairs
  • International
  • Sport
  • Health
  • Education
  • IT&C knowledge
  • Arts & Lifestyle
  • Opinions
  • Elections 2025
  • Environment
About Us
Contact
Privacy policy
Terms and conditions
Quickly scroll through news digests and see how they are covered in different publications!
  • News
  • Exclusive
    • INSCOP Surveys
    • Podcast
    • EU
    • Diaspora
    • Republic of Moldova
    • Politics
    • Economy
    • Current Affairs
    • International
    • Sport
    • Health
    • Education
    • IT&C knowledge
    • Arts & Lifestyle
    • Opinions
    • Elections 2025
    • Environment
80 new news items in the last 24 hours
  1. Home
  2. Internațional

The European Union has approved the Kisunla medication for the treatment of Alzheimer's disease, imposing strict conditions regarding its administration.

Matei Gaginsky
whatsapp
facebook
linkedin
x
copy-link copy-link
26 September 2025, 09:29
main event image
International
Foto: https://www.pexels.com/
google-preference

Always see our news on Google

The European Commission has approved Kisunla, a treatment for mild cognitive impairments, including dementia in the early stages of Alzheimer's disease. Although the drug, based on the molecule donanemab, has shown promising results in clinical trials, controversy remains regarding its actual benefits and the risks of serious side effects. The authorization is conditional on its administration only to patients without genetic mutations that could increase the risks. EU member states have the freedom to decide on reimbursement, and other countries, such as the United Kingdom, have adopted a similar approach.

Sources

sursa imagine
News.ro
Uniunea Europeană autorizează Kisunla, un tratament al Eli Lilly controversat împotriva maladiei Alzheimer. În afară de beneficii reale modeste, are efecte secundare grave, uneori mortale, şi anume hemoragii şi edeme cerebrale
sursa imagine
Cotidianul
UE a aprobat un nou medicament pentru Alzheimer
sursa imagine
DCNews
UE a aprobat un nou tratament controversat împotriva Alzheimer
sursa imagine
Stirile ProTV
Noi tratamente împotriva Alzheimer: UE a autorizat un medicament promițător, dar cu efecte secundare grave posibile
sursa imagine
G4Media
Noi tratamente împotriva Alzheimer: UE autorizează medicamentul Kisunla, produs de Eli Lilly
sursa imagine
Stiripesurse
Noi tratamente împotriva Alzheimer: UE autorizează medicamentul Kisunla, produs de Eli Lilly
sursa imagine
Gandul
O nouă speranță pentru pacienții cu ALZHEIMER. Comisia Europeană aprobă primul tratament care poate încetini evoluția bolii
sursa imagine
Digi24
Comisia Europeană a autorizat comercializarea unui medicament pentru tratarea bolii Alzheimer în stadii incipiente

Latest News

11:50

Cristela Georgescu sent a message of thanks to the thousands of Romanians who took to the streets of Rome in support of her husband

11:42

The company owned by Cristela Georgescu recorded losses of 18,310 lei in 2025

11:37

The Trump administration would encourage Viktor Orbán to run for UN secretary-general, with possible support from Russia and China (WSJ)

11:30

ANM announces heavy rain and strong winds in nine counties on Tuesday and Wednesday

11:23

A press investigation highlights irregularities in the purchase of three electric vehicles by the Mogoșești Town Hall in Iași County

See more news

NEWS ON THE SAME TOPICS

event image
Health
Alzheimer’s drug tested on people without symptoms. Researchers want to find out whether the disease can be prevented
event image
Current Affairs
INSP warns: 12,173 new cases of Alzheimer’s were reported last year in Romania
event image
Health
The U.S. Food and Drug Administration has approved a drug that doubles the survival rate of patients with advanced pancreatic cancer.
event image
EU
European support for patients unable to pay upfront for treatment in another EU country, proposed in Parliament
event image
EU
Commission makes Sanofi’s commitments on communications about rival flu vaccine Fluad binding
app preview
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
app preview app preview
Alzheimer's disease EU pharmaceutical industry

Editor’s Recommendations

main event image
Opinions
43 minutes ago

Democracy and Its Trials: Lessons for Romania

main event image
Opinions
2 hours ago
Editorials and opinions

Did our team win?

main event image
Exclusive
2 hours ago
Original Content

October 26, 2026. TV: What was discussed last night on the news channels

main event image
Exclusive
59 minutes ago

SPECIAL Informat.ro / Top international politics topics from the past week. Peace negotiations regarding the war in Ukraine, the Starlink dispute, and energy as a geopolitical stake

main event image
Exclusive
1 hour ago

EXCLUSIVE Top sports topics from the past week / Tributes in Romanian sport and spectacular duels in the Champions League

app preview
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
app preview
app store badge google play badge
  • News
  • Exclusive
  • INSCOP Surveys
  • Podcast
  • EU
  • Diaspora
  • Republic of Moldova
  • Politics
  • Economy
  • Current Affairs
  • International
  • Sport
  • Health
  • Education
  • IT&C knowledge
  • Arts & Lifestyle
  • Opinions
  • Elections 2025
  • Environment
  • About Us
  • Contact
Privacy policy
Cookies Policy
Terms and conditions
Open source licenses
All rights reserved Strategic Media Team SRL

Technology in partnership with

anpc-sal anpc-sol